Alphamab Oncology has announced that their Investigational New Drug $(IND.AU)$ application for JSKN022 has been officially accepted by the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China. JSKN022 is an innovative bispecific antibody-drug conjugate targeting programmed death ligand 1 (PD-L1) and integrin αvβ6, developed independently by Alphamab. This marks a significant step forward as there are currently no approved ADCs targeting integrin αvβ6 or PD-L1 globally. The company plans to commence a first-in-human clinical study for treating advanced malignant solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.